25 XP   0   0   10

Integrated Biopharma Inc
Buy, Hold or Sell?

Let's analyse Integrated Biopharma Inc together

PenkeI guess you are interested in Integrated Biopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Integrated Biopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Integrated Biopharma Inc

I send you an email if I find something interesting about Integrated Biopharma Inc.

Quick analysis of Integrated Biopharma Inc (30 sec.)










What can you expect buying and holding a share of Integrated Biopharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.62
Expected worth in 1 year
$0.61
How sure are you?
77.5%

+ What do you gain per year?

Total Gains per Share
$0.00
Return On Investment
-1.3%

For what price can you sell your share?

Current Price per Share
$0.22
Expected price per share
$0.18 - $0.23
How sure are you?
50%

1. Valuation of Integrated Biopharma Inc (5 min.)




Live pricePrice per Share (EOD)

$0.22

Intrinsic Value Per Share

$-0.74 - $-0.24

Total Value Per Share

$-0.12 - $0.38

2. Growth of Integrated Biopharma Inc (5 min.)




Is Integrated Biopharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$18.5m$18.2m$557.7k3.0%

How much money is Integrated Biopharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$96.2k$550.2k-$646.5k-671.7%
Net Profit Margin-0.8%3.9%--

How much money comes from the company's main activities?

3. Financial Health of Integrated Biopharma Inc (5 min.)




4. Comparing to competitors in the Packaged Foods industry (5 min.)




  Industry Rankings (Packaged Foods)  


Richest
#406 / 496

Most Revenue
#411 / 496

Most Profit
#360 / 496

Most Efficient
#365 / 496

What can you expect buying and holding a share of Integrated Biopharma Inc? (5 min.)

Welcome investor! Integrated Biopharma Inc's management wants to use your money to grow the business. In return you get a share of Integrated Biopharma Inc.

What can you expect buying and holding a share of Integrated Biopharma Inc?

First you should know what it really means to hold a share of Integrated Biopharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Integrated Biopharma Inc is $0.2196. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Integrated Biopharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Integrated Biopharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.62. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Integrated Biopharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.01-5.8%0.00-1.4%0.028.3%0.0312.7%0.028.1%
Usd Book Value Change Per Share-0.01-4.8%0.00-0.3%0.029.8%0.0313.7%0.0210.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-4.8%0.00-0.3%0.029.8%0.0313.7%0.0210.7%
Usd Price Per Share0.25-0.31-0.52-0.52-0.34-
Price to Earnings Ratio-4.92-23.23--33.13-0.88-0.41-
Price-to-Total Gains Ratio-23.52-131.24-165.86-69.96-22.36-
Price to Book Ratio0.41-0.50-0.87-1.84-1.45-
Price-to-Total Gains Ratio-23.52-131.24-165.86-69.96-22.36-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2196
Number of shares4553
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.03
Usd Total Gains Per Share0.000.03
Gains per Quarter (4553 shares)-3.25136.89
Gains per Year (4553 shares)-13.01547.58
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-13-230548538
20-26-36010951086
30-39-49016431634
40-52-62021902182
50-65-75027382730
60-78-88032853278
70-91-101038333826
80-104-114043814374
90-117-127049284922
100-130-140054765470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%8.04.00.066.7%16.04.00.080.0%28.011.01.070.0%50.011.034.052.6%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%31.09.00.077.5%58.037.00.061.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%17.00.078.017.9%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%31.09.00.077.5%58.037.00.061.1%

Fundamentals of Integrated Biopharma Inc

About Integrated Biopharma Inc

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Fundamental data was last updated by Penke on 2024-03-10 06:03:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Integrated Biopharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Integrated Biopharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Integrated Biopharma Inc to the Packaged Foods industry mean.
  • A Net Profit Margin of -3.3% means that $-0.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Integrated Biopharma Inc:

  • The MRQ is -3.3%. The company is making a loss. -1
  • The TTM is -0.8%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ-3.3%TTM-0.8%-2.5%
TTM-0.8%YOY3.9%-4.7%
TTM-0.8%5Y5.6%-6.4%
5Y5.6%10Y3.8%+1.8%
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.3%3.2%-6.5%
TTM-0.8%2.8%-3.6%
YOY3.9%3.0%+0.9%
5Y5.6%3.2%+2.4%
10Y3.8%3.6%+0.2%
1.1.2. Return on Assets

Shows how efficient Integrated Biopharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Integrated Biopharma Inc to the Packaged Foods industry mean.
  • -1.5% Return on Assets means that Integrated Biopharma Inc generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Integrated Biopharma Inc:

  • The MRQ is -1.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM-0.4%-1.1%
TTM-0.4%YOY2.1%-2.5%
TTM-0.4%5Y3.5%-3.9%
5Y3.5%10Y2.5%+1.0%
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.5%1.2%-2.7%
TTM-0.4%1.1%-1.5%
YOY2.1%1.0%+1.1%
5Y3.5%1.2%+2.3%
10Y2.5%1.2%+1.3%
1.1.3. Return on Equity

Shows how efficient Integrated Biopharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Integrated Biopharma Inc to the Packaged Foods industry mean.
  • -2.1% Return on Equity means Integrated Biopharma Inc generated $-0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Integrated Biopharma Inc:

  • The MRQ is -2.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.1%TTM-0.5%-1.5%
TTM-0.5%YOY3.1%-3.6%
TTM-0.5%5Y13.8%-14.4%
5Y13.8%10Y10.3%+3.6%
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.1%2.6%-4.7%
TTM-0.5%2.2%-2.7%
YOY3.1%2.2%+0.9%
5Y13.8%2.4%+11.4%
10Y10.3%2.5%+7.8%

1.2. Operating Efficiency of Integrated Biopharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Integrated Biopharma Inc is operating .

  • Measures how much profit Integrated Biopharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Integrated Biopharma Inc to the Packaged Foods industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Integrated Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.2%-0.2%
TTM0.2%YOY2.4%-2.3%
TTM0.2%5Y5.2%-5.1%
5Y5.2%10Y4.7%+0.5%
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.3%-5.3%
TTM0.2%3.3%-3.1%
YOY2.4%4.8%-2.4%
5Y5.2%5.2%+0.0%
10Y4.7%4.9%-0.2%
1.2.2. Operating Ratio

Measures how efficient Integrated Biopharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Packaged Foods industry mean).
  • An Operation Ratio of 1.99 means that the operating costs are $1.99 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Integrated Biopharma Inc:

  • The MRQ is 1.994. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.943. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.994TTM1.943+0.051
TTM1.943YOY1.876+0.067
TTM1.9435Y0.967+0.976
5Y0.96710Y0.936+0.031
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9941.524+0.470
TTM1.9431.505+0.438
YOY1.8761.460+0.416
5Y0.9671.404-0.437
10Y0.9361.226-0.290

1.3. Liquidity of Integrated Biopharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Integrated Biopharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Packaged Foods industry mean).
  • A Current Ratio of 2.93 means the company has $2.93 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Integrated Biopharma Inc:

  • The MRQ is 2.926. The company is able to pay all its short-term debts. +1
  • The TTM is 3.006. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.926TTM3.006-0.081
TTM3.006YOY2.856+0.150
TTM3.0065Y2.038+0.968
5Y2.03810Y1.492+0.546
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9261.554+1.372
TTM3.0061.595+1.411
YOY2.8561.610+1.246
5Y2.0381.655+0.383
10Y1.4921.583-0.091
1.3.2. Quick Ratio

Measures if Integrated Biopharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Integrated Biopharma Inc to the Packaged Foods industry mean.
  • A Quick Ratio of 0.64 means the company can pay off $0.64 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Integrated Biopharma Inc:

  • The MRQ is 0.640. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.752. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.640TTM0.752-0.112
TTM0.752YOY0.776-0.024
TTM0.7525Y0.592+0.160
5Y0.59210Y0.475+0.118
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6400.565+0.075
TTM0.7520.581+0.171
YOY0.7760.644+0.132
5Y0.5920.708-0.116
10Y0.4750.717-0.242

1.4. Solvency of Integrated Biopharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Integrated Biopharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Integrated Biopharma Inc to Packaged Foods industry mean.
  • A Debt to Asset Ratio of 0.28 means that Integrated Biopharma Inc assets are financed with 27.8% credit (debt) and the remaining percentage (100% - 27.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Integrated Biopharma Inc:

  • The MRQ is 0.278. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.283. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.278TTM0.283-0.004
TTM0.283YOY0.307-0.025
TTM0.2835Y0.535-0.252
5Y0.53510Y1.043-0.508
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2780.488-0.210
TTM0.2830.490-0.207
YOY0.3070.481-0.174
5Y0.5350.487+0.048
10Y1.0430.491+0.552
1.4.2. Debt to Equity Ratio

Measures if Integrated Biopharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Integrated Biopharma Inc to the Packaged Foods industry mean.
  • A Debt to Equity ratio of 38.5% means that company has $0.39 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Integrated Biopharma Inc:

  • The MRQ is 0.385. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.395. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.385TTM0.395-0.009
TTM0.395YOY0.451-0.056
TTM0.3955Y2.796-2.402
5Y2.79610Y5.088-2.292
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3850.961-0.576
TTM0.3950.984-0.589
YOY0.4510.936-0.485
5Y2.7960.995+1.801
10Y5.0881.060+4.028

2. Market Valuation of Integrated Biopharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Integrated Biopharma Inc generates.

  • Above 15 is considered overpriced but always compare Integrated Biopharma Inc to the Packaged Foods industry mean.
  • A PE ratio of -4.92 means the investor is paying $-4.92 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Integrated Biopharma Inc:

  • The EOD is -4.326. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.925. Based on the earnings, the company is expensive. -2
  • The TTM is 23.233. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-4.326MRQ-4.925+0.599
MRQ-4.925TTM23.233-28.157
TTM23.233YOY-33.127+56.360
TTM23.2335Y0.884+22.349
5Y0.88410Y0.406+0.478
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
EOD-4.32613.175-17.501
MRQ-4.92512.324-17.249
TTM23.23313.017+10.216
YOY-33.12711.502-44.629
5Y0.88416.260-15.376
10Y0.40619.312-18.906
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Integrated Biopharma Inc:

  • The EOD is -1.295. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.475. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 0.020. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-1.295MRQ-1.475+0.179
MRQ-1.475TTM0.020-1.495
TTM0.020YOY-4.639+4.659
TTM0.0205Y0.003+0.017
5Y0.00310Y0.085-0.082
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
EOD-1.2954.748-6.043
MRQ-1.4754.039-5.514
TTM0.0201.787-1.767
YOY-4.639-0.075-4.564
5Y0.0031.465-1.462
10Y0.0851.630-1.545
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Integrated Biopharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Packaged Foods industry mean).
  • A PB ratio of 0.41 means the investor is paying $0.41 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Integrated Biopharma Inc:

  • The EOD is 0.356. Based on the equity, the company is cheap. +2
  • The MRQ is 0.405. Based on the equity, the company is cheap. +2
  • The TTM is 0.497. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.356MRQ0.405-0.049
MRQ0.405TTM0.497-0.092
TTM0.497YOY0.872-0.375
TTM0.4975Y1.839-1.341
5Y1.83910Y1.454+0.385
Compared to industry (Packaged Foods)
PeriodCompanyIndustry (mean)+/- 
EOD0.3561.431-1.075
MRQ0.4051.486-1.081
TTM0.4971.433-0.936
YOY0.8721.776-0.904
5Y1.8391.856-0.017
10Y1.4542.407-0.953
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Integrated Biopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.011-0.001-93%0.021-150%0.030-135%0.023-145%
Book Value Per Share--0.6170.623-1%0.605+2%0.394+56%0.076+707%
Current Ratio--2.9263.006-3%2.856+2%2.038+44%1.492+96%
Debt To Asset Ratio--0.2780.283-2%0.307-9%0.535-48%1.043-73%
Debt To Equity Ratio--0.3850.395-2%0.451-15%2.796-86%5.088-92%
Dividend Per Share----0%-0%-0%-0%
Eps---0.013-0.003-76%0.018-169%0.028-146%0.018-171%
Free Cash Flow Per Share---0.0420.002-2146%0.034-225%0.016-363%0.010-522%
Free Cash Flow To Equity Per Share---0.0420.002-2329%0.008-657%0.002-2546%0.003-1319%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Intrinsic Value_10Y_max---0.239--------
Intrinsic Value_10Y_min---0.741--------
Intrinsic Value_1Y_max--0.057--------
Intrinsic Value_1Y_min--0.021--------
Intrinsic Value_3Y_max--0.111--------
Intrinsic Value_3Y_min---0.019--------
Intrinsic Value_5Y_max--0.089--------
Intrinsic Value_5Y_min---0.149--------
Market Cap6609872.160-14%7524902.5009330877.325-19%15651792.000-52%15674818.459-52%10221749.044-26%
Net Profit Margin---0.033-0.008-75%0.039-185%0.056-159%0.038-187%
Operating Margin---0.002-100%0.024-100%0.052-100%0.047-100%
Operating Ratio--1.9941.943+3%1.876+6%0.967+106%0.936+113%
Pb Ratio0.356-14%0.4050.497-18%0.872-54%1.839-78%1.454-72%
Pe Ratio-4.326+12%-4.92523.233-121%-33.127+573%0.884-657%0.406-1312%
Price Per Share0.220-14%0.2500.310-19%0.520-52%0.521-52%0.340-26%
Price To Free Cash Flow Ratio-1.295+12%-1.4750.020-7306%-4.639+215%0.003-46191%0.085-1834%
Price To Total Gains Ratio-20.656+12%-23.515131.243-118%165.856-114%69.961-134%22.359-205%
Quick Ratio--0.6400.752-15%0.776-18%0.592+8%0.475+35%
Return On Assets---0.015-0.004-75%0.021-170%0.035-143%0.025-159%
Return On Equity---0.021-0.005-75%0.031-167%0.138-115%0.103-120%
Total Gains Per Share---0.011-0.001-93%0.021-150%0.030-135%0.023-145%
Usd Book Value--18566000.00018763500.000-1%18205750.000+2%11868850.000+56%2300300.000+707%
Usd Book Value Change Per Share---0.011-0.001-93%0.021-150%0.030-135%0.023-145%
Usd Book Value Per Share--0.6170.623-1%0.605+2%0.394+56%0.076+707%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.013-0.003-76%0.018-169%0.028-146%0.018-171%
Usd Free Cash Flow---1275576.00062356.000-2146%1016500.000-225%485771.200-363%302235.600-522%
Usd Free Cash Flow Per Share---0.0420.002-2146%0.034-225%0.016-363%0.010-522%
Usd Free Cash Flow To Equity Per Share---0.0420.002-2329%0.008-657%0.002-2546%0.003-1319%
Usd Market Cap6609872.160-14%7524902.5009330877.325-19%15651792.000-52%15674818.459-52%10221749.044-26%
Usd Price Per Share0.220-14%0.2500.310-19%0.520-52%0.521-52%0.340-26%
Usd Profit---382000.000-96250.000-75%550250.000-169%838350.000-146%536000.000-171%
Usd Revenue--11509000.00012629000.000-9%13370250.000-14%13767100.000-16%12092925.000-5%
Usd Total Gains Per Share---0.011-0.001-93%0.021-150%0.030-135%0.023-145%
 EOD+3 -5MRQTTM+6 -27YOY+8 -255Y+11 -2210Y+12 -22

3.2. Fundamental Score

Let's check the fundamental score of Integrated Biopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.326
Price to Book Ratio (EOD)Between0-10.356
Net Profit Margin (MRQ)Greater than0-0.033
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.640
Current Ratio (MRQ)Greater than12.926
Debt to Asset Ratio (MRQ)Less than10.278
Debt to Equity Ratio (MRQ)Less than10.385
Return on Equity (MRQ)Greater than0.15-0.021
Return on Assets (MRQ)Greater than0.05-0.015
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Integrated Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.267
Ma 20Greater thanMa 500.225
Ma 50Greater thanMa 1000.228
Ma 100Greater thanMa 2000.241
OpenGreater thanClose0.220
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Reconciled Depreciation  28317300-1299-1298-595-297
Tax Provision  1020301343-3013-83-70



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets25,721
Total Liabilities7,155
Total Stockholder Equity18,566
 As reported
Total Liabilities 7,155
Total Stockholder Equity+ 18,566
Total Assets = 25,721

Assets

Total Assets25,721
Total Current Assets17,065
Long-term Assets8,656
Total Current Assets
Cash And Cash Equivalents 732
Net Receivables 3,733
Inventory 12,149
Other Current Assets 451
Total Current Assets  (as reported)17,065
Total Current Assets  (calculated)17,065
+/-0
Long-term Assets
Property Plant Equipment 3,805
Long-term Assets Other 57
Long-term Assets  (as reported)8,656
Long-term Assets  (calculated)3,862
+/- 4,794

Liabilities & Shareholders' Equity

Total Current Liabilities5,833
Long-term Liabilities1,322
Total Stockholder Equity18,566
Total Current Liabilities
Accounts payable 3,305
Total Current Liabilities  (as reported)5,833
Total Current Liabilities  (calculated)3,305
+/- 2,528
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt2,274
Long-term Liabilities  (as reported)1,322
Long-term Liabilities  (calculated)2,274
+/- 952
Total Stockholder Equity
Total Stockholder Equity (as reported)18,566
Total Stockholder Equity (calculated)0
+/- 18,566
Other
Capital Stock60
Common Stock Shares Outstanding 30,100
Net Invested Capital 18,566
Net Working Capital 11,232
Property Plant and Equipment Gross 11,697



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
10,400
8,580
9,748
10,135
9,984
9,838
10,604
9,964
9,338
10,007
9,925
11,192
12,447
20,827
22,358
24,480
24,503
31,813
30,170
28,234
31,227
26,242
27,964
29,527
30,810
37,605
40,155
41,843
43,610
44,209
46,564
42,087
34,892
31,357
30,165
22,647
19,781
16,483
16,195
16,627
14,503
13,848
13,401
13,660
13,228
13,650
13,409
11,530
10,752
11,877
12,174
13,587
12,727
12,611
12,567
11,766
10,322
11,583
13,144
13,661
12,420
11,623
12,077
14,220
14,112
14,085
14,647
14,998
13,614
15,196
13,381
15,648
14,621
14,568
19,724
22,575
22,221
19,790
19,641
19,971
20,645
22,944
24,630
25,263
26,131
25,440
24,336
27,071
27,697
25,250
26,364
26,052
26,880
25,431
26,642
25,721
25,72126,64225,43126,88026,05226,36425,25027,69727,07124,33625,44026,13125,26324,63022,94420,64519,97119,64119,79022,22122,57519,72414,56814,62115,64813,38115,19613,61414,99814,64714,08514,11214,22012,07711,62312,42013,66113,14411,58310,32211,76612,56712,61112,72713,58712,17411,87710,75211,53013,40913,65013,22813,66013,40113,84814,50316,62716,19516,48319,78122,64730,16531,35734,89242,08746,56444,20943,61041,84340,15537,60530,81029,52727,96426,24231,22728,23430,17031,81324,50324,48022,35820,82712,44711,1929,92510,0079,3389,96410,6049,8389,98410,1359,7488,58010,400
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,698
0
0
0
0
0
0
0
0
9,239
7,846
9,166
10,486
11,117
9,994
9,322
9,833
11,939
11,730
12,070
12,704
13,087
11,636
12,551
10,635
13,212
12,294
12,154
13,733
16,540
16,350
14,079
14,083
14,536
15,297
16,461
18,574
19,099
20,526
17,998
16,984
19,347
20,043
16,626
17,063
16,385
17,508
16,372
17,759
17,065
17,06517,75916,37217,50816,38517,06316,62620,04319,34716,98417,99820,52619,09918,57416,46115,29714,53614,08314,07916,35016,54013,73312,15412,29413,21210,63512,55111,63613,08712,70412,07011,73011,9399,8339,3229,99411,11710,4869,1667,8469,2390000000011,6980000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,201
5,628
1,308
2,156
1,524
3,880
1,583
873
1,082
381
781
570
1,987
1,518
735
648
1,048
1,583
606
563
1,386
388
649
145
216
124
285
55
480
819
868
983
826
580
886
572
585
561
951
896
593
567
697
597
284
54
62
228
365
45
431
475
525
67
565
402
369
43
105
210
57
162
264
331
1,168
1,085
2,529
1,316
2,594
732
7322,5941,3162,5291,0851,168331264162572101054336940256567525475431453652286254284597697567593896951561585572886580826983868819480552851242161456493881,3865636061,5831,0486487351,5181,9875707813811,0828731,5833,8801,5242,1561,3085,6282,20100000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
2,000
2,000
0
0
2,000
0
0
0
0
0
0
0
0
0
0
0
0
0
823
823
823
823
823
823
823
684
684
684
684
684
532
532
532
532
501
501
501
501
501
501
501
501
465
382
215
263
196
0
0
0
84
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000008400019626321538246550150150150150150150150153253253253268468468468468482382382382382382382300000000000002,000002,0002,0002,00000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,960
0
0
0
0
0
0
0
0
2,289
1,940
2,179
2,297
3,385
2,788
2,638
2,803
3,991
3,634
3,135
3,765
4,420
2,706
4,843
2,673
5,171
3,198
4,467
3,381
4,517
4,957
4,973
3,904
4,879
4,272
5,507
4,855
4,537
7,917
9,044
3,801
5,467
6,170
4,888
3,711
4,509
4,683
4,511
4,172
3,733
3,7334,1724,5114,6834,5093,7114,8886,1705,4673,8019,0447,9174,5374,8555,5074,2724,8793,9044,9734,9574,5173,3814,4673,1985,1712,6734,8432,7064,4203,7653,1353,6343,9912,8032,6382,7883,3852,2972,1791,9402,289000000001,9600000000000000000000000000000000000000000000000
       Other Current Assets 
358
390
456
486
542
392
983
403
384
170
257
333
886
806
2,319
4,215
2,436
1,281
1,752
1,439
1,576
822
638
627
1,346
4,508
4,823
4,670
4,751
4,175
4,153
5,499
3,560
1,958
2,350
953
1,080
754
699
783
649
556
560
482
3,337
3,895
3,843
3,538
454
391
439
332
344
339
342
331
370
306
389
1,463
1,210
334
522
368
1,211
518
673
686
353
510
636
505
479
481
387
443
413
461
407
3,353
394
317
594
603
3,050
2,749
504
597
513
340
516
527
359
284
482
451
4514822843595275163405135975042,7493,0506035943173943,3534074614134433874814795056365103536866735181,2113685223341,2101,4633893063703313423393443324393914543,5383,8433,8953,3374825605566497836997541,0809532,3501,9583,5605,4994,1534,1754,7514,6704,8234,5081,3466276388221,5761,4391,7521,2812,4364,2152,319806886333257170384403983392542486456390358
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,711
0
0
0
0
0
0
0
0
2,527
2,476
2,417
2,658
1,483
1,649
2,301
2,080
2,281
1,486
1,780
1,536
1,498
1,978
1,601
2,746
1,860
2,327
1,651
2,365
2,522
2,472
5,062
4,914
2,383
596
6,483
1,606
1,857
1,637
1,742
7,352
7,724
7,654
8,624
9,301
9,667
9,372
9,059
8,883
8,656
8,6568,8839,0599,3729,6679,3018,6247,6547,7247,3521,7421,6371,8571,6066,4835962,3834,9145,0622,4722,5222,3651,6512,3271,8602,7461,6011,9781,4981,5361,7801,4862,2812,0802,3011,6491,4832,6582,4172,4762,527000000001,7110000000000000000000000000000000000000000000000
       Property Plant Equipment 
1,409
1,367
2,574
2,502
2,438
2,350
2,364
2,328
2,346
2,308
2,436
2,360
2,325
2,294
5,156
5,943
6,785
6,857
7,677
7,546
7,451
4,664
4,510
4,350
4,222
4,173
4,066
4,084
4,168
4,377
4,275
4,132
3,942
3,886
3,688
3,442
1,940
1,865
1,824
1,859
1,790
1,719
1,780
1,768
1,631
1,598
1,519
1,445
1,466
1,449
1,359
1,289
1,299
1,235
1,168
1,205
1,231
1,239
1,531
1,483
1,431
1,373
1,368
1,488
1,486
1,567
1,536
1,498
1,654
1,601
1,632
1,684
1,670
1,651
1,604
1,806
1,802
1,778
1,745
1,720
1,698
4,520
1,670
1,651
1,637
1,742
3,982
3,913
3,931
3,777
4,496
4,842
4,558
4,276
4,108
3,805
3,8054,1084,2764,5584,8424,4963,7773,9313,9133,9821,7421,6371,6511,6704,5201,6981,7201,7451,7781,8021,8061,6041,6511,6701,6841,6321,6011,6541,4981,5361,5671,4861,4881,3681,3731,4311,4831,5311,2391,2311,2051,1681,2351,2991,2891,3591,4491,4661,4451,5191,5981,6311,7681,7801,7191,7901,8591,8241,8651,9403,4423,6883,8863,9424,1324,2754,3774,1684,0844,0664,1734,2224,3504,5104,6647,4517,5467,6776,8576,7855,9435,1562,2942,3252,3602,4362,3082,3462,3282,3642,3502,4382,5022,5741,3671,409
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,643
688
688
688
688
145
145
145
145
145
145
145
145
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000000000001451451451451451451451456886886886881,6430000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
507
497
487
1,020
3,678
4,167
4,247
4,178
4,639
4,532
3,618
3,547
3,721
3,820
4,161
4,111
4,056
5,531
6,263
6,114
6,106
6,051
5,165
1,743
1,683
1,631
1,570
1,535
1,501
1,466
1,432
1,397
1,363
0
0
0
0
1,188
1,154
1,119
1,085
1,051
1,017
983
948
914
880
846
811
777
743
712
688
663
235
0
0
0
134
0
0
0
33
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000330001340002356636887127437778118468809149489831,0171,0511,0851,1191,1541,18800001,3631,3971,4321,4661,5011,5351,5701,6311,6831,7435,1656,0516,1066,1146,2635,5314,0564,1114,1613,8203,7213,5473,6184,5324,6394,1784,2474,1673,6781,02048749750700000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
192
0
0
0
0
0
0
0
0
374
331
298
281
0
218
185
0
105
0
213
0
0
324
0
237
176
124
0
121
57
48
3,284
3,169
86
3,054
2,824
2,780
2,656
0
0
0
0
53
49
44
61
58
57
57
57
575757586144495300002,6562,7802,8243,054863,1693,28448571210124176237032400213010501852180281298331374000000001920000000000000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
877
0
533
0
640
659
622
0
0
577
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000057700622659640053308770000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
3,521
2,207
2,452
3,459
3,613
3,646
3,591
2,743
1,976
2,422
2,154
3,094
2,773
2,572
7,745
7,939
9,062
7,416
7,463
7,816
9,395
10,272
10,028
10,322
11,234
11,872
13,900
20,493
20,866
24,212
27,733
25,919
18,579
20,494
18,373
18,487
19,139
18,929
17,928
19,074
18,702
19,544
18,928
19,538
19,959
21,345
20,731
19,629
19,585
22,260
23,529
24,125
23,797
22,901
22,559
21,360
20,366
21,738
22,896
22,864
21,729
20,939
21,142
23,341
23,193
22,412
22,321
22,728
21,091
21,125
19,485
22,095
20,677
19,804
19,529
22,109
20,832
17,897
17,421
16,777
16,501
16,877
17,514
16,830
16,382
11,106
9,445
11,001
10,722
6,675
7,743
7,400
8,139
6,570
7,756
7,155
7,1557,7566,5708,1397,4007,7436,67510,72211,0019,44511,10616,38216,83017,51416,87716,50116,77717,42117,89720,83222,10919,52919,80420,67722,09519,48521,12521,09122,72822,32122,41223,19323,34121,14220,93921,72922,86422,89621,73820,36621,36022,55922,90123,79724,12523,52922,26019,58519,62920,73121,34519,95919,53818,92819,54418,70219,07417,92818,92919,13918,48718,37320,49418,57925,91927,73324,21220,86620,49313,90011,87211,23410,32210,02810,2729,3957,8167,4637,4169,0627,9397,7452,5722,7733,0942,1542,4221,9762,7433,5913,6463,6133,4592,4522,2073,521
   > Total Current Liabilities 
3,480
1,629
2,407
3,418
3,585
3,553
3,569
2,725
1,962
2,412
2,149
3,089
2,768
2,572
7,573
7,939
9,062
7,416
7,463
7,816
9,395
10,272
10,028
10,322
11,234
11,872
13,900
20,493
20,866
15,862
19,483
25,919
14,864
10,038
7,729
14,579
15,166
14,890
15,088
15,983
18,702
19,544
18,928
19,538
19,959
21,345
20,731
19,629
19,585
12,203
12,496
13,192
12,766
12,416
12,117
11,071
10,207
11,653
12,933
13,441
12,542
11,865
12,149
14,362
12,304
11,824
11,791
11,988
10,536
11,155
9,865
12,531
11,313
16,180
12,576
15,511
14,437
12,353
12,542
12,293
12,388
13,099
14,644
14,265
14,372
9,236
7,701
9,384
9,233
5,263
5,814
5,188
6,160
4,828
6,197
5,833
5,8336,1974,8286,1605,1885,8145,2639,2339,3847,7019,23614,37214,26514,64413,09912,38812,29312,54212,35314,43715,51112,57616,18011,31312,5319,86511,15510,53611,98811,79111,82412,30414,36212,14911,86512,54213,44112,93311,65310,20711,07112,11712,41612,76613,19212,49612,20319,58519,62920,73121,34519,95919,53818,92819,54418,70215,98315,08814,89015,16614,5797,72910,03814,86425,91919,48315,86220,86620,49313,90011,87211,23410,32210,02810,2729,3957,8167,4637,4169,0627,9397,5732,5722,7683,0892,1492,4121,9622,7253,5693,5533,5853,4182,4071,6293,480
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,305
0
0
0
0
0
0
0
0
4,832
4,017
4,709
5,335
6,205
5,240
5,193
4,926
6,689
5,040
5,220
5,844
5,758
5,454
5,794
5,556
6,095
5,553
5,667
5,550
7,229
7,161
5,834
4,799
6,337
4,574
6,869
5,659
6,331
5,687
3,630
0
0
0
0
0
0
0
0
0
0
00000000003,6305,6876,3315,6596,8694,5746,3374,7995,8347,1617,2295,5505,6675,5536,0955,5565,7945,4545,7585,8445,2205,0406,6894,9265,1935,2406,2055,3354,7094,0174,8320000000012,3050000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,950
4,739
15,261
1,031
869
852
6,042
851
903
7,161
6,881
5,852
6,337
4,574
6,869
5,659
6,331
5,687
3,630
1,509
3,158
2,728
133
0
0
0
42
0
0
00420001332,7283,1581,5093,6305,6876,3315,6596,8694,5746,3375,8526,8817,1619038516,0428528691,03115,2614,7394,9500000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
2,527
1,358
1,062
2,054
2,261
2,176
2,118
1,993
1,550
1,632
1,366
2,408
2,182
1,978
2,293
2,482
3,617
1,937
1,875
2,257
3,507
3,987
3,902
3,710
5,205
4,124
5,913
3,896
3,558
3,594
5,551
5,766
4,300
6,630
4,503
5,143
6,355
5,788
5,153
5,915
5,672
6,440
5,264
5,659
4,175
5,152
5,608
3,366
4,839
6,481
6,407
7,028
6,520
5,883
5,625
6,239
6,190
6,944
7,598
7,236
7,302
11,804
7,223
12,858
12,460
11,886
5,947
12,263
5,797
5,361
10,163
12,117
11,399
10,513
7,026
8,282
7,276
3,855
5,106
5,478
7,330
4,358
8,491
7,441
8,190
5,106
4,221
4,243
4,690
3,209
3,529
2,955
3,533
2,266
3,536
3,305
3,3053,5362,2663,5332,9553,5293,2094,6904,2434,2215,1068,1907,4418,4914,3587,3305,4785,1063,8557,2768,2827,02610,51311,39912,11710,1635,3615,79712,2635,94711,88612,46012,8587,22311,8047,3027,2367,5986,9446,1906,2395,6255,8836,5207,0286,4076,4814,8393,3665,6085,1524,1755,6595,2646,4405,6725,9155,1535,7886,3555,1434,5036,6304,3005,7665,5513,5943,5583,8965,9134,1245,2053,7103,9023,9873,5072,2571,8751,9373,6172,4822,2931,9782,1822,4081,3661,6321,5501,9932,1182,1762,2612,0541,0621,3582,527
       Other Current Liabilities 
376
221
300
447
506
644
413
406
156
656
647
638
577
540
649
633
684
732
834
857
1,187
1,613
1,454
1,940
1,357
2,505
2,336
2,222
2,897
3,574
3,676
3,048
3,422
3,328
3,226
2,420
1,579
1,644
2,246
1,963
1,571
1,357
1,562
1,476
3,179
3,588
2,818
3,658
2,141
1,549
1,594
1,438
1,296
1,122
1,279
1,190
1,284
1,309
1,199
1,291
1,474
3,942
1,189
3,794
5,554
1,211
1,118
4,707
1,120
1,184
3,766
3,883
1,264
3,624
0
0
0
5,544
0
3,058
484
488
494
3,058
495
2,370
0
0
0
0
0
0
0
0
0
0
00000000002,3704953,0584944884843,05805,5440003,6241,2643,8833,7661,1841,1204,7071,1181,2115,5543,7941,1893,9421,4741,2911,1991,3091,2841,1901,2791,1221,2961,4381,5941,5492,1413,6582,8183,5883,1791,4761,5621,3571,5711,9632,2461,6441,5792,4203,2263,3283,4223,0483,6763,5742,8972,2222,3362,5051,3571,9401,4541,6131,187857834732684633649540577638647656156406413644506447300221376
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,289
10,159
10,085
9,963
9,423
9,187
0
8,993
0
139
5,306
10,530
0
9,840
9,970
0
0
3,725
0
3,319
3,077
2,988
5,544
4,879
1,904
4,113
3,778
2,870
2,565
2,010
1,870
1,744
1,617
1,489
1,412
1,929
2,212
1,979
1,742
1,559
1,322
1,3221,5591,7421,9792,2121,9291,4121,4891,6171,7441,8702,0102,5652,8703,7784,1131,9044,8795,5442,9883,0773,31903,725009,9709,840010,5305,30613908,99309,1879,4239,96310,08510,15910,2890000000000000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,647
4,500
4,359
4,423
4,302
4,080
0
3,830
0
0
5,306
4,870
0
4,605
4,246
0
0
3,725
0
3,319
3,077
2,988
0
2,177
1,904
1,648
1,436
654
0
40
0
0
0
0
0
0
0
0
0
0
0
000000000004006541,4361,6481,9042,17702,9883,0773,31903,725004,2464,60504,8705,306003,83004,0804,3024,4234,3594,5004,6470000000000000000000000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
877
0
533
0
640
659
622
0
0
577
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000057700622659640053308770000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
69
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
350
250
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
563
1,648
991
1,165
696
770
687
677
717
503
56
15
12
15
9
139
76
444
808
715
503
621
436
382
0
0
0
0
2,822
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000002,8220000382436621503715808444761399151215565037176776877706961,1659911,648563000000000000000000250350000000000000000000000006900000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
687
677
717
503
56
15
0
15
0
139
0
444
0
0
503
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000503004440139015015565037176776870000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
6,879
6,373
7,296
6,676
6,371
6,192
7,013
7,221
7,362
7,585
7,771
8,098
9,674
18,255
14,613
16,541
15,441
24,397
22,707
20,047
21,461
15,621
17,619
18,972
19,365
25,577
26,137
21,350
22,744
19,997
18,831
16,168
16,313
10,863
11,792
4,160
642
0
0
0
0
0
0
0
0
0
-7,322
0
0
0
0
0
0
0
0
-9,594
-10,044
-10,155
-9,752
-9,203
-9,309
-9,316
-9,065
-9,121
-9,081
-8,327
-7,674
-7,730
-7,477
-5,929
-6,104
-6,447
-6,056
-5,236
195
466
1,389
1,893
2,220
3,194
4,144
6,067
7,116
8,433
9,749
14,334
14,891
16,070
16,975
18,575
18,621
18,652
18,741
18,861
18,886
18,566
18,56618,88618,86118,74118,65218,62118,57516,97516,07014,89114,3349,7498,4337,1166,0674,1443,1942,2201,8931,389466195-5,236-6,056-6,447-6,104-5,929-7,477-7,730-7,674-8,327-9,081-9,121-9,065-9,316-9,309-9,203-9,752-10,155-10,044-9,59400000000-7,3220000000006424,16011,79210,86316,31316,16818,83119,99722,74421,35026,13725,57719,36518,97217,61915,62121,46120,04722,70724,39715,44116,54114,61318,2559,6748,0987,7717,5857,3627,2217,0136,1926,3716,6767,2966,3736,879
   Common Stock
10
10
12
13
13
12
12
12
12
12
12
12
20
20
21
21
21
25
25
25
25
25
25
25
26
26
27
27
28
28
28
29
29
30
40
40
40
40
40
41
41
41
41
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
59
59
59
59
59
59
59
59
59
59
60
60
60
60
60
60
60
60
0
60
0
0
006006060606060606060595959595959595959594242424242424242424242424242424242424242424242424242424242424241414141404040404030292928282827272626252525252525252121212020121212121212121313121010
   Retained Earnings 
2,021
1,544
1,218
597
283
95
916
1,124
1,265
1,488
1,674
2,001
2,219
2,382
1,530
1,068
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-51,818
0
0
0
0
0
0
0
0
-54,105
-54,555
-54,670
-54,267
-53,718
-53,824
-53,935
-53,692
-53,756
-53,723
-52,977
-52,328
-52,405
-52,167
-50,631
-50,810
-51,158
-50,770
-49,952
-49,793
-49,547
-48,624
-48,264
-47,952
-46,993
-46,057
-44,156
-43,115
-41,891
-40,650
-36,143
-35,627
-34,596
-33,799
-32,305
-32,340
-32,395
-32,379
-32,339
-32,398
-32,780
-32,780-32,398-32,339-32,379-32,395-32,340-32,305-33,799-34,596-35,627-36,143-40,650-41,891-43,115-44,156-46,057-46,993-47,952-48,264-48,624-49,547-49,793-49,952-50,770-51,158-50,810-50,631-52,167-52,405-52,328-52,977-53,723-53,756-53,692-53,935-53,824-53,718-54,267-54,670-54,555-54,10500000000-51,8180000000000000000000000000000001,0681,5302,3822,2192,0011,6741,4881,2651,124916952835971,2181,5442,021
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,553
0
0
0
0
0
0
0
0
44,568
44,568
44,572
44,572
44,572
44,572
44,676
44,684
44,692
44,699
44,707
44,711
44,732
44,747
44,759
44,763
44,768
44,771
44,773
50,028
50,053
50,053
50,197
50,212
50,227
50,241
50,263
50,271
50,364
50,438
50,516
0
0
0
0
0
0
0
0
0
0
000000000050,51650,43850,36450,27150,26350,24150,22750,21250,19750,05350,05350,02844,77344,77144,76844,76344,75944,74744,73244,71144,70744,69944,69244,68444,67644,57244,57244,57244,57244,56844,5680000000044,5530000000000000000000000000000000000000000000000
   Treasury Stock0000000000-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-99-29-29-29-29-29-29-29-28-29-29-29-29-29-29-29-29-290
   Other Stockholders Equity 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue50,672
Cost of Revenue-46,611
Gross Profit4,0614,061
 
Operating Income (+$)
Gross Profit4,061
Operating Expense-50,552
Operating Income120-46,491
 
Operating Expense (+$)
Research Development0
Selling General Administrative3,941
Selling And Marketing Expenses0
Operating Expense50,5523,941
 
Net Interest Income (+$)
Interest Income0
Interest Expense-40
Other Finance Cost-12
Net Interest Income-52
 
Pretax Income (+$)
Operating Income120
Net Interest Income-52
Other Non-Operating Income Expenses0
Income Before Tax (EBT)10088
EBIT - interestExpense = 80
100
6
Interest Expense40
Earnings Before Interest and Taxes (EBIT)120140
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax100
Tax Provision-134
Net Income From Continuing Ops-34-34
Net Income-34
Net Income Applicable To Common Shares-34
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net3252
 

Technical Analysis of Integrated Biopharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Integrated Biopharma Inc. The general trend of Integrated Biopharma Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Integrated Biopharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Integrated Biopharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.23 < 0.23 < 0.23.

The bearish price targets are: 0.2 > 0.18 > 0.18.

Tweet this
Integrated Biopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Integrated Biopharma Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Integrated Biopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Integrated Biopharma Inc. The current macd is -0.00170473.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Integrated Biopharma Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Integrated Biopharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Integrated Biopharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Integrated Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartIntegrated Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Integrated Biopharma Inc. The current adx is 71.25.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Integrated Biopharma Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Integrated Biopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Integrated Biopharma Inc. The current sar is 0.1908.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Integrated Biopharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Integrated Biopharma Inc. The current rsi is 43.27. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Integrated Biopharma Inc Daily Relative Strength Index (RSI) ChartIntegrated Biopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Integrated Biopharma Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Integrated Biopharma Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Integrated Biopharma Inc Daily Stochastic Oscillator ChartIntegrated Biopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Integrated Biopharma Inc. The current cci is -36.92568609.

Integrated Biopharma Inc Daily Commodity Channel Index (CCI) ChartIntegrated Biopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Integrated Biopharma Inc. The current cmo is -19.11664234.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Integrated Biopharma Inc Daily Chande Momentum Oscillator (CMO) ChartIntegrated Biopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Integrated Biopharma Inc. The current willr is -26.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Integrated Biopharma Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Integrated Biopharma Inc Daily Williams %R ChartIntegrated Biopharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Integrated Biopharma Inc.

Integrated Biopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Integrated Biopharma Inc. The current atr is 0.00720592.

Integrated Biopharma Inc Daily Average True Range (ATR) ChartIntegrated Biopharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Integrated Biopharma Inc. The current obv is -1,083,300.

Integrated Biopharma Inc Daily On-Balance Volume (OBV) ChartIntegrated Biopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Integrated Biopharma Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Integrated Biopharma Inc Daily Money Flow Index (MFI) ChartIntegrated Biopharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Integrated Biopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-21MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Integrated Biopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Integrated Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.267
Ma 20Greater thanMa 500.225
Ma 50Greater thanMa 1000.228
Ma 100Greater thanMa 2000.241
OpenGreater thanClose0.220
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Integrated Biopharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Integrated Biopharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Integrated Biopharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Integrated Biopharma Inc

I send you an email if I find something interesting about Integrated Biopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Integrated Biopharma Inc.

Receive notifications about Integrated Biopharma Inc in your mailbox!